There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SQZ Biotechnologies (SQZ – Research Report) and Imunon (IMNN – Research Report) with bullish sentiments.
SQZ Biotechnologies (SQZ)
In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on SQZ Biotechnologies, with a price target of $42.00. The company’s shares closed last Monday at $2.30, close to its 52-week low of $2.00.
According to TipRanks.com, Cann is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SQZ Biotechnologies with a $42.00 average price target.
See the top stocks recommended by analysts >>
Imunon (IMNN)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Imunon, with a price target of $16.00. The company’s shares closed last Monday at $1.71, close to its 52-week low of $1.54.
According to TipRanks.com, Bodnar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Imunon has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SQZ:
- Financial Institutions, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call
- Old National Celebrates First Better Together Volunteer Event
- CFRA Keeps Their Buy Rating on Tesla (TSLA)
- CFRA Sticks to Their Buy Rating for Apple (AAPL)
- Cryptocurrencies to Watch for the Week of October 2
